Wells Fargo & Company Bio Xcel Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$468,5370.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$171,8670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$116,2360.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$50,6480.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny129KShares$50,2210.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $10.9M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...